Stockscreener 앱 받기
0.1057
25.91%
0.0208
Glucotrack Inc 주식(GCTK)의 최신 뉴스
GlucoTrack Achieves ISO13485:2016 Certification for CBGM - TipRanks
Glucotrack Announces ISO 13485:2016 Certification - The Manila Times
Glucotrack Achieves Critical ISO 13485 Certification for Glucose Monitoring Technology - StockTitan
US Equities Close Mixed as Tech Gains Offset Weakness in Defensive Sectors – Market - HPBL
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Why Taiwan Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket - Benzinga
GCTK Stock Plummets to 52-Week Low of $0.09 Amid Market Turbulence - Investing.com Nigeria
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
GCTK Stock Plummets to 52-Week Low of $0.09 Amid Market Turbulence By Investing.com - Investing.com South Africa
Glucotrack appoints new VP to enhance diabetes monitor rollout By Investing.com - Investing.com South Africa
Glucotrack Strenghtens Leadership Team with Addition of Industry Veteran as Vice President of Regulatory Affairs - The Manila Times
Glucotrack appoints new VP to enhance diabetes monitor rollout - Investing.com
Glucotrack Strengthens Leadership: 25-Year CGM Expert Ted Williams Joins as Regulatory VP - StockTitan
Why Vision Marine Technologies Shares Are Trading Higher By 68%; Here Are 20 Stocks Moving Premarket - Benzinga
Glucotrack issues new shares for warrant exchange - Investing.com
Pre-market Movers: SAGE, ITCI, GCTK, MRNA... - RTTNews
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket - Benzinga
GlucoTrack (NASDAQ: GCTK) Approves Increase in Authorized Shares**WASHINGTON, D.C. 20549 – GlucoTrack, Inc. (NASDAQ: GCTK) reported on January 3, 2025, that they held a Special Meeting of its stockholders in which they approved an amendment - Defense World
iShares Russell Top 200 Value ETF (NYSEARCA:IWX) Stock Price Up 0.1% – Should You Buy? - Defense World
Goldbank Mining (CVE:GLB) Shares Down 22.2% – What’s Next? - Defense World
iShares J.P. Morgan EM Local Currency Bond ETF (NYSEARCA:LEMB) Shares Down 0% – What’s Next? - Defense World
Maverix Metals (CVE:MMX) Trading Up 4.7% – Should You Buy? - Defense World
GlucoTrack to Present at TechBio Showcase 2025 - TipRanks
Glucotrack to Present at TechBio Showcase™ 2025 - The Manila Times
Glucotrack CEO to Present Revolutionary Blood Glucose Monitor at TechBio Showcase 2025 - StockTitan
Glucotrack's Innovative Continuous Blood Glucose Monitor Poised to Transform Diabetes Management - Citybuzz
Advancing Clinical Studies, Meeting Regulatory Milestones, Strengthening Its Strategic Framework And More: The Past Year For Glucotrack, And What Lies Ahead - Nasdaq
Contrasting GlucoTrack (NASDAQ:GCTK) & Accuray (NASDAQ:ARAY) - Defense World
GCTK stock touches 52-week low at $0.18 amid market challenges - Investing.com
6,770 Shares in Apple Inc. (NASDAQ:AAPL) Bought by Sensible Financial Planning & Management LLC. - Defense World
SABBY MANAGEMENT, LLC Acquires Significant Stake in GlucoTrack I - GuruFocus.com
Glucotrack Receives Notice from Nasdaq Regarding Bid Price Rule Compliance**Washington, D.C., December 31, 2024 – Glucotrack, Inc. (NASDAQ: GCTK) recently received notification from the Nasdaq Stock Market LLC (“Nasdaq”) concerning its bid price f - Defense World
ENGlobal (NASDAQ:ENG) Coverage Initiated at StockNews.com - Defense World
Glucotrack inks sales agreement for $8.23M stock offering - Investing.com
Glucotrack inks sales agreement for $8.23M stock offering By Investing.com - Investing.com Canada
GCTK Stock Plummets to 52-Week Low at $0.21 Amid Market Struggles - Investing.com Australia
Glucose Monitoring Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies - GlobalData
Glucotrack Initiates Human Clinical Trials for Innovative Implantable Continuous Blood Glucose Monitor - Citybuzz
Driving Innovation In Diabetes Management: Glucotrack Begins Enrollment For Human Clinical Trials For Its Implantable Continuous Blood Glucose Monitor - Nasdaq
Glucotrack begins enrollment for first human trial of continuous blood glucose monitor - Drug Delivery Business News
0.59%
자본화:
|
볼륨(24시간):